Ligand Pharmaceuticals Enters Material Definitive Agreement
Ticker: LGNZZ · Form: 8-K · Filed: Sep 16, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $55 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
Related Tickers: LGND
TL;DR
Ligand Pharma signed a big deal, creating new financial obligations.
AI Summary
Ligand Pharmaceuticals Inc. entered into a material definitive agreement on September 12, 2025. This agreement also created a direct financial obligation for the company. The filing includes financial statements and exhibits related to this event.
Why It Matters
This filing indicates a significant new contract or financial commitment for Ligand Pharmaceuticals, which could impact its future financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements and new financial obligations can introduce significant risks and opportunities that require careful evaluation.
Key Players & Entities
- Ligand Pharmaceuticals Inc. (company) — Registrant
- September 12, 2025 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Ligand Pharmaceuticals enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on September 12, 2025.
What is the nature of the direct financial obligation created?
The filing states that a direct financial obligation was created but does not provide specific details about its terms or amount.
Are the financial statements and exhibits related to the new agreement?
Yes, the filing indicates that financial statements and exhibits are included in relation to the material definitive agreement and the creation of a financial obligation.
What is Ligand Pharmaceuticals' principal executive office address?
Ligand Pharmaceuticals' principal executive offices are located at 555 Heritage Drive, Suite 200, Jupiter, FL 33458.
When was this 8-K filing submitted?
This 8-K filing was submitted on September 16, 2025.
Filing Stats: 736 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-09-16 17:19:53
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Ma
- $55 million — e the Company to maintain not less than $55 million of consolidated EBITDA (as defined in t
Filing Documents
- d92764d8k.htm (8-K) — 26KB
- d92764dex101.htm (EX-10.1) — 979KB
- 0001193125-25-205147.txt ( ) — 1363KB
- lgnd-20250912.xsd (EX-101.SCH) — 3KB
- lgnd-20250912_lab.xml (EX-101.LAB) — 18KB
- lgnd-20250912_pre.xml (EX-101.PRE) — 11KB
- d92764d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 10.1 Third Amendment to Credit Agreement, dated as of September 12, 2025, to that certain Credit Agreement, dated as of October 12, 2023, by and among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer (each as defined therein), as amended by that certain First Amendment to Credit Agreement, dated as of July 8, 2024 and as amended by that certain Second Amendment to Credit Agreement, dated as of August 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: September 16, 2025 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary